Agios Pharmaceuticals CEO Brian Goff's Performance Share Units Vesting and Tax Withholding Sales

This Form 4 filing reports that Brian Goff, CEO and Director of Agios Pharmaceuticals, had performance share units (PSUs) vest on April 2, 2026. Two separate PSU grants vested: 25,528 shares from an August 8, 2022 grant (15% of total) and 13,500 shares from a March 1, 2024 grant (25% of total), both triggered by achievement of specified regulatory milestones. Following vesting, shares were automatically sold to cover tax withholding obligations: 12,472 shares at $34.71 per share from the first grant and 6,596 shares at $34.71 per share from the second grant, both executed under Rule 10b5-1 plans established in the original PSU agreements. After these transactions, Goff's total direct common stock holdings increased to 184,508 shares. The filing represents routine executive compensation transactions related to performance-based equity awards rather than discretionary trading activity.